| Gut microbiome influences efficacy of PD-1–based immunotherapy against epithelial tumors B Routy, E Le Chatelier, L Derosa, CPM Duong, MT Alou, R Daillère, ... Science 359 (6371), 91-97, 2018 | 4519 | 2018 |
| Anticancer immunotherapy by CTLA-4 blockade relies on the gut microbiota M Vétizou, JM Pitt, R Daillère, P Lepage, N Waldschmitt, C Flament, ... Science 350 (6264), 1079-1084, 2015 | 3145 | 2015 |
| Enterococcus hirae and Barnesiella intestinihominis Facilitate Cyclophosphamide-Induced Therapeutic Immunomodulatory Effects R Daillère, M Vétizou, N Waldschmitt, T Yamazaki, C Isnard, ... Immunity 45 (4), 931-943, 2016 | 766 | 2016 |
| Caloric restriction mimetics enhance anticancer immunosurveillance F Pietrocola, J Pol, E Vacchelli, S Rao, DP Enot, EE Baracco, S Levesque, ... Cancer cell 30 (1), 147-160, 2016 | 505 | 2016 |
| A threshold level of intratumor CD8+ T-cell PD1 expression dictates therapeutic response to anti-PD1 SF Ngiow, A Young, N Jacquelot, T Yamazaki, D Enot, L Zitvogel, ... Cancer research 75 (18), 3800-3811, 2015 | 250 | 2015 |
| Sustained Type I interferon signaling as a mechanism of resistance to PD-1 blockade N Jacquelot, T Yamazaki, MP Roberti, CPM Duong, MC Andrews, ... Cell research 29 (10), 846-861, 2019 | 201 | 2019 |
| Predictors of responses to immune checkpoint blockade in advanced melanoma N Jacquelot, MP Roberti, DP Enot, S Rusakiewicz, N Ternès, S Jegou, ... Nature communications 8 (1), 592, 2017 | 198 | 2017 |
| Anticancer immunotherapy by CTLA-4 blockade: obligatory contribution of IL-2 receptors and negative prognostic impact of soluble CD25 D Hannani, M Vétizou, D Enot, S Rusakiewicz, N Chaput, D Klatzmann, ... Cell research 25 (2), 208-224, 2015 | 196 | 2015 |
| The neuropeptide VIP confers anticipatory mucosal immunity by regulating ILC3 activity C Seillet, K Luong, J Tellier, N Jacquelot, RD Shen, P Hickey, VC Wimmer, ... Nature immunology 21 (2), 168-177, 2020 | 157 | 2020 |
| The neuropeptide VIP confers anticipatory mucosal immunity by regulating ILC3 activity C Seillet, K Luong, J Tellier, N Jacquelot, RD Shen, P Hickey, VC Wimmer, ... Nature immunology 21 (2), 168-177, 2020 | 155 | 2020 |
| Blockade of the co-inhibitory molecule PD-1 unleashes ILC2-dependent antitumor immunity in melanoma N Jacquelot, C Seillet, M Wang, A Pizzolla, Y Liao, S Hediyeh-Zadeh, ... Nature immunology 22 (7), 851-864, 2021 | 131 | 2021 |
| TumGrowth: An open-access web tool for the statistical analysis of tumor growth curves DP Enot, E Vacchelli, N Jacquelot, L Zitvogel, G Kroemer OncoImmunology 7 (9), e1462431, 2018 | 115 | 2018 |
| Innate lymphoid cells and cancer N Jacquelot, C Seillet, E Vivier, GT Belz Nature Immunology 23 (3), 371-379, 2022 | 97 | 2022 |
| Mature cytotoxic CD56bright/CD16+ natural killer cells can infiltrate lymph nodes adjacent to metastatic melanoma M Messaoudene, G Fregni, E Fourmentraux-Neves, J Chanal, E Maubec, ... Cancer research 74 (1), 81-92, 2014 | 94 | 2014 |
| Increased lipid metabolism impairs NK cell function and mediates adaptation to the lymphoma environment T Kobayashi, PY Lam, H Jiang, K Bednarska, R Gloury, V Murigneux, ... Blood, The Journal of the American Society of Hematology 136 (26), 3004-3017, 2020 | 91 | 2020 |
| Tertiary lymphoid structures and B lymphocytes in cancer prognosis and response to immunotherapies N Jacquelot, J Tellier, N Sl, B Gt Oncoimmunology 10 (1), 2021 | 78 | 2021 |
| Chemokine receptor patterns in lymphocytes mirror metastatic spreading in melanoma N Jacquelot, DP Enot, C Flament, N Vimond, C Blattner, JM Pitt, ... The Journal of clinical investigation 126 (3), 921-937, 2016 | 71 | 2016 |
| Targeting chemokines and chemokine receptors in melanoma and other cancers N Jacquelot, CPM Duong, GT Belz, L Zitvogel Frontiers in immunology 9, 2480, 2018 | 69 | 2018 |
| Metastasis-Entrained Eosinophils Enhance Lymphocyte-Mediated Antitumor Immunity S Grisaru-Tal, S Dulberg, L Beck, C Zhang, M Itan, S Hediyeh-Zadeh, ... Cancer Research 81 (21), 5555-5571, 2021 | 59 | 2021 |
| Regulation of CD4+ NKG2D+ Th1 cells in patients with metastatic melanoma treated with sorafenib: role of IL-15Rα and NKG2D triggering AI Romero, N Chaput, V Poirier-Colame, S Rusakiewicz, N Jacquelot, ... Cancer research 74 (1), 68-80, 2014 | 55 | 2014 |
Laurence ZitvogelInstitut Gustave Roussy, Université de Paris Saclay, INSERM在 igr.fr 的电子邮件经过验证
